Innate Pharma (IPHA)
NASDAQ:IPHA
Want to see IPHA full AI Analyst Report?
IPHA Stock Chart & Stats
$1.66
-$0.03(-1.61%)
At close: 4:00 PM EST
$1.66
-$0.03(-1.61%)
Day’s Range― - ―
52-Week Range$1.17 - $2.63
Previous CloseN/A
Volume6.24K
Average Volume (3M)386.19K
Market Cap
$170.81M
Enterprise Value$145.85M
Total Cash (Recent Filing)$34.30M
Total Debt (Recent Filing)$22.56M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Sep 17, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding93,921,860
10 Day Avg. Volume29,239
30 Day Avg. Volume386,189
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)-6.14
Price to Sales (P/S)47.79
P/FCF Ratio-2.62
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue52.33
Enterprise Value/Gross Profit52.33
Enterprise Value/Ebitda-2.62
Forecast
1Y Price Target
$6.50Price Target Upside291.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.3
Revenue Forecast (FY)$35.97M
Bulls Say, Bears Say
Bulls Say
Partnerships And Milestone UpsideLarge, structured collaborations with AstraZeneca provide meaningful non-dilutive financing potential and validation of Innate’s programs. Remaining milestone pools and potential royalties create durable optionality to fund development, reduce cash pressure, and increase upside if partnered assets advance to commercialization.
Regulatory Progress For LacutamabRegulatory clearance and multiple expedited designations materially strengthen the clinical and commercialization pathway for lacutamab, raising the probability of accelerated review and market access. This structural regulatory momentum supports long‑term value capture and clearer timelines for registrational evidence generation.
Differentiated Pipeline Asset (IPH4502)IPH4502’s early efficacy signals and distinct ADC design (exatecan payload, hydrophilic/cleavable linker) suggest potential best‑in‑class positioning in certain indications. If confirmed, this durable technological differentiation expands strategic partnering, licensing and commercial optionality across multiple tumor types.
Bears Say
Negative Shareholders' EquityNegative shareholders’ equity reflects cumulative losses that materially weaken capital structure and borrowing capacity. Over the medium term this elevates refinancing and covenant risk, constrains strategic optionality, and increases the likelihood of dilutive equity raises or onerous financing terms to sustain development programs.
Persistent Cash Burn And Limited RunwaySustained negative operating cash flow and a sub‑year runway mean the company must secure financing or partner funding to execute late‑stage trials. This structural liquidity gap increases execution risk, can delay program starts, and raises the probability of dilutive capital raises that affect long‑term shareholder economics.
Low Recurring Revenue Vs High OpExVery low and volatile revenue that is largely grant/licensing based leaves operating costs massively outpacing internal income. This weak operating leverage limits self‑funding, increases dependency on milestone receipts or external capital, and reduces predictability of long‑term sustainable cash generation.
Innate Pharma News
IPHA FAQ
What was Innate Pharma’s price range in the past 12 months?
Innate Pharma lowest stock price was $1.17 and its highest was $2.63 in the past 12 months.
What is Innate Pharma’s market cap?
Innate Pharma’s market cap is $170.81M.
When is Innate Pharma’s upcoming earnings report date?
Innate Pharma’s upcoming earnings report date is Sep 17, 2026 which is in 106 days.
How were Innate Pharma’s earnings last quarter?
Innate Pharma released its earnings results on Mar 26, 2026. The company reported -$0.358 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.216.
Is Innate Pharma overvalued?
According to Wall Street analysts Innate Pharma’s price is currently Undervalued.
Does Innate Pharma pay dividends?
Innate Pharma does not currently pay dividends.
What is Innate Pharma’s EPS estimate?
Innate Pharma’s EPS estimate is -0.21.
How many shares outstanding does Innate Pharma have?
Innate Pharma has 93,921,860 shares outstanding.
What happened to Innate Pharma’s price movement after its last earnings report?
Innate Pharma reported an EPS of -$0.358 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went down -2.344%.
Which hedge fund is a major shareholder of Innate Pharma?
Currently, no hedge funds are holding shares in IPHA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innate Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (291.57% Upside)
$6.50 (291.57% Upside)
Blogger Sentiment
Bullish
IPHA Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.68%
12-Months-Change
Fundamentals
Return on Equity
593.93%
Trailing 12-Months
Asset Growth
-35.95%
Trailing 12-Months
Company Description
Innate Pharma
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
IPHA Company Deck
IPHA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call featured multiple meaningful clinical and regulatory milestones (FDA clearance for lacutamab Phase III, completed PACIFIC-9 enrollment, encouraging early IPH4502 data, and high-value partnership milestone potential) and demonstrated cost discipline with lower R&D spend. Offsetting these positives are material near-term financing and execution risks: modest reported revenue (EUR 9M), a high burn rate (EUR 63M operating expenses), and a limited cash runway (EUR 44.8M through Q3 2026) that makes initiation of late-stage programs dependent on partner deals or other financing. Clinical data are promising but still early and need confirmation. Overall, the company shows strong programmatic momentum and partnership upside, but material funding and timing risks balance that optimism.View all IPHA earnings summariesIPHA Stock 12 Month Forecast
Average Price Target
$6.50
▲(291.57% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Sangamo Therapeutics
―
―
Elicio Therapeutics
―
Vor Biopharma
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.09% Other Institutional Investors
99.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---